Navigation Links
Tandem Diabetes Care Prices Initial Public Offering
Date:11/13/2013

SAN DIEGO, Nov. 13, 2013 /PRNewswire/ -- Tandem Diabetes Care®, Inc. ("Tandem"), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price of $15.00 per share.  In addition, Tandem has granted the underwriters a 30-day  option to purchase up to an additional 1,200,000 shares at the initial public offering price.  All of the shares are being offered by Tandem. The shares are expected to begin trading tomorrow, November 14, 2013, on the NASDAQ Global Market under the ticker symbol "TNDM." The offering is expected to close on November 19, 2013, pending customary closing conditions.

BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers for the offering. Deutsche Bank Securities and Stifel are acting as co-managers.  

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on November 13, 2013. When available, copies of the final prospectus may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038 Attention: Prospectus Department, by email at dg.Prospectus_Requests@baml.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.


'/>"/>
SOURCE Tandem Diabetes Care, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TANDEM DIABETES CARE BECOMES PRESENTING SPONSOR OF THE GREATEST AWARDS SHOW IN DIABETES
2. Tandem Diabetes Care Announces FDA Clearance of t:connect Diabetes Management Application for Use with t:slim Insulin Pump
3. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
4. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
5. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
6. Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical
7. Organogenesis Launches Fight4MyFeet for Diabetes Patient and Healthcare Provider Communities
8. The Diabetes and Sleep Apnea Connection
9. New Tech Tools Help Fight Diabetes
10. JDRF Teams Up with Pfizers Centers for Therapeutic Innovation to Support Novel Translational Research in Type 1 Diabetes
11. T1D Exchange Awarded $2.8M Grant by JDRF to Study Metformin and Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):